Integration of a tele-dermatology model for Epidermolysis Bullosa improves patient outreach: a before and after observational study.
Remote dermatology services expand specialty care access for rare blistering diseases in underserved regions.
This study describes a tele-dermatology implementation for Epidermolysis Bullosa care in an Indian setting, showing improved patient reach following digital integration. While methodologically limited by before/after design and single-institution scope, it contributes to the evidence base for telemedicine as an access intervention for ultra-rare blistering diseases with no curative treatment.
What the study was
- Study design
- before_after_observational
- Population
- Epidermolysis Bullosa patients in India
- Category
- Public Health
- Maturity
- Validated
- Journal
- Frontiers in Digital Health
Why it surfaced
EB is a priority rare disease with emerging gene therapies (beremagene geperpavec); digital health access studies inform real-world deployment of future EB treatments in low-resource settings; relevant for rare disease pipeline context.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.